Eli Lilly and Company

Other

Princeton University

Lynn Stacy Gossett

Alan M Warshawsky

Donald Paul Matthews

Chuan Shih

Samuel James Dominianni

Dawn Alisa Brooks

Christopher J Rito

Leonard Larry Winneroski, Jr

Robert J Ardecky

Guoxin Zhu

Scott Eugene Conner

Pierre-Yves Michellys

Anthony John Shuker

John S Tyhonas

David A Hay

Edward C Taylor

Winton Dennis Jones, Jr

Alexander Glenn Godfrey

Daryl Lynn Smith

Jonathan Edward Green

Allie Edward Tripp

Jennifer Ann Vance

Ying Kwong Yee

James Robert Henry

Yanping Xu

Nathan Bryan Mantlo

Jose Eduardo Lopez

Daniel Ray Mayhugh

Quanrong Shen

Xiaodong Wang

James T Metz

Christopher John Rit

Koo Lee

William J Gill

The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, R1, RP, Z, L, LL, RP, RN, and Zare defined herein, their preparation, pharmaceutical compositions, and methods of use. 

Vitamin D receptor modulators

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Sulfonamide derivatives as PPAR modulators

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists

The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

Modulators of peroxisome proliferator activated receptors (PPAR)

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Modulators of peroxisome proliferator activated receptors

5,6,7,8-tetrahydropyrido[2,3-D]pyrimidines

2-Amino-4-hydroxy-4,5,6,7-tetrahydropyrido�2,3-d!pyrimidine derivatives of aromatic amides, such as a benzamide or thienylcarboxamide in which the amino portion of the amide is other than L-glutamic acid are inhibitors of enzymes which utilize folic acid, in particular glycinamide ribonucleotide formyl transferase. A typical embodiment is N-(N-{4-�2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido�2,3-d!pyrimidin-6-y l)ethyl!benzoyl}-L-.gamma.-glutamyl)-D-aspartic acid.

Pyridopyrimidines as nonclassical antifolates

The present invention provides novel pyrimidinyl-glutamic acid derivatives and intermediates thereto. Further provided are methods for inhibiting dihydrofolate reductase in mammals and for treating susceptible neoplasms in mammals, particularly humans.

Pyrimidinyl-glutamic acid derivatives

2-amino-4-hydroxypyrido[2,3-d]pyrimidines, having a 6-substituted ethyl or ethenyl group, are useful antineoplastic agents.

6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents

This invention relates to N-[2-amino-4-substituted-[[(pyrrolo or pyrido) [2,3-d]pyrimidinyl]-alkyl]benzoyl]-L-glutamic acid compounds, intermediates for their synthesis, pharmaceutical formulations containing those compounds, and their use as antineoplastic agents.

N-[2-amino-4-substituted[[(pyrrollo or

Growing community of inventors

Indianapolis, IN, United States of America

Lynn Stacy Gossett